Western blot analysis of RIPK1 using anti-RIPK1 antibody (PA2051).
Anti-RIP/RIPK1 Antibody Picoband(r)
PA2051
ApplicationsWestern Blot
Product group Antibodies
ReactivityHamster, Human
TargetRIPK1
Overview
- SupplierBoster Bio
- Product NameAnti-RIP Antibody
- Delivery Days Customer9
- Antibody SpecificityNo cross reactivity with other proteins.
- Application Supplier NoteWB: The detection limit for RIPK1 is approximately 1ng/lane under reducing conditions. Tested Species: In-house tested species with positive results. Predicted Species: Species predicted to be fit for the product based on sequence similarities. Other applications have not been tested. Optimal dilutions should be determined by end users.
- ApplicationsWestern Blot
- Applications SupplierWB
- CertificationResearch Use Only
- ClonalityPolyclonal
- Concentration500 ug/ml
- FormulationLyophilized
- Gene ID8737
- Target nameRIPK1
- Target descriptionreceptor interacting serine/threonine kinase 1
- Target synonymsAIEFL; cell death protein RIP; IMD57; receptor (TNFRSF)-interacting serine-threonine kinase 1; receptor-interacting protein 1; receptor-interacting protein kinase 1; receptor-interacting serine/threonine-protein kinase 1; RIP; RIP1; RIP-1; serine/threonine-protein kinase RIP
- HostRabbit
- IsotypeIgG
- Protein IDQ13546
- Protein NameReceptor-interacting serine/threonine-protein kinase 1
- Scientific DescriptionBoster Bio Anti-RIP/RIPK1 Antibody catalog # PA2051. Tested in WB applications. This antibody reacts with Human. The brand Picoband indicates this is a premium antibody that guarantees superior quality, high affinity, and strong signals with minimal background in Western blot applications. Only our best-performing antibodies are designated as Picoband, ensuring unmatched performance.
- ReactivityHamster, Human
- Reactivity SupplierHuman, Hamster
- Storage Instruction-20°C,2°C to 8°C
- UNSPSC12352203
References
- The p53-inducible long noncoding RNA TRINGS protects cancer cells from necrosis under glucose starvation. Khan MR et al., 2017 Dec 1, EMBO JRead more